Publicaciones en colaboración con investigadores/as de Universidad del País Vasco/Euskal Herriko Unibertsitatea (29)

2024

  1. Efficacy of the combination of amphotericin B and echinocandins against Candida auris in vitro and in the Caenorhabditis elegans host model

    Microbiology spectrum, Vol. 12, Núm. 1, pp. e0208623

  2. Medication impact on oral health in schizophrenia

    Medicina Oral Patologia Oral y Cirugia Bucal, Vol. 29, Núm. 1, pp. e51-e57

2023

  1. In Vitro and In Vivo Activity of Citral in Combination with Amphotericin B, Anidulafungin and Fluconazole against Candida auris Isolates

    Journal of Fungi, Vol. 9, Núm. 6

  2. Non-Adherence in Adult Male Patients with Community-Acquired Pneumonia: Relative Forgiveness of Amoxicillin versus Respiratory Fluoroquinolones

    Antibiotics, Vol. 12, Núm. 5

  3. PK/PD modeling and simulation of the in vitro activity of the combinations of isavuconazole with echinocandins against Candida auris

    CPT: Pharmacometrics and Systems Pharmacology, Vol. 12, Núm. 6, pp. 770-782

2022

  1. Farmako antipsikotikoak eta aho-patologia: eragin kaltegarriak jakinarazteko Europako sistemaren bidezko analisia

    Osagaiz: osasun-zientzien aldizkaria, Vol. 6, Núm. 1, pp. 55-66

  2. In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study

    Frontiers in Cellular and Infection Microbiology, Vol. 12

  3. Postantifungal Effect of Antifungal Drugs against Candida: What Do We Know and How Can We Apply This Knowledge in the Clinical Setting?

    Journal of Fungi, Vol. 8, Núm. 7

2021

  1. In vitro interaction and killing-kinetics of amphotericin b combined with anidulafungin or caspofungin against candida auris

    Pharmaceutics, Vol. 13, Núm. 9

  2. In vitro pharmacokinetic/pharmacodynamic modelling and simulation of amphotericin b against candida auris

    Pharmaceutics, Vol. 13, Núm. 11

  3. In vitro synergistic interactions of isavuconazole and echinocandins against Candida auris

    Antibiotics, Vol. 10, Núm. 4

2019

  1. Killing kinetics of anidulafungin, caspofungin and micafungin against Candida parapsilosis species complex: Evaluation of the fungicidal activity

    Revista Iberoamericana de Micologia, Vol. 36, Núm. 1, pp. 24-29

  2. Postantifungal effect of anidulafungin against Candida albicans, Candida dubliniensis, Candida Africana, Candida parapsilosis, Candida metapsilosis and Candida orthopsilosis

    Revista Espanola de Quimioterapia, Vol. 32, Núm. 2, pp. 183-188

  3. Therapeutic tools for oral candidiasis: Current and new antifungal drugs

    Medicina oral, patologia oral y cirugia bucal, Vol. 24, Núm. 2, pp. e172-e180

2016

  1. In vitro pharmacodynamic modelling of anidulafungin against Candida spp.

    International Journal of Antimicrobial Agents, Vol. 47, Núm. 3, pp. 178-183

  2. Postantifungal effect of caspofungin against the Candida albicans and Candida parapsilosis clades

    Diagnostic Microbiology and Infectious Disease, Vol. 86, Núm. 2, pp. 172-177

2015

  1. Comparison of the in vitro activity of echinocandins against Candida albicans, Candida dubliniensis, and Candida africana by time-kill curves

    Diagnostic Microbiology and Infectious Disease, Vol. 82, Núm. 1, pp. 57-61

  2. In Vitro fungicidal activities of anidulafungin, caspofungin, and micafungin against Candida glabrata, Candida bracarensis, and Candida nivariensis evaluated by time-kill studies

    Antimicrobial Agents and Chemotherapy, Vol. 59, Núm. 6, pp. 3615-3618

  3. La utilidad clínica de los derivados triazólicos en el tratamiento de las infecciones fúngicas

    Revista Espanola de Quimioterapia, Vol. 28, Núm. 4, pp. 169-182

  4. Postantifungal effect of micafungin against the species complexes of Candida albicans and Candida parapsilosis

    PLoS ONE, Vol. 10, Núm. 7